Medical use for tachykinin antagonists
AssigneeGlaxo Group Limited
InventorRussell Michael Hagan
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of NK1 antagonists, in the treatment of depression. Also described are novel NK1 antagonists of formula (I), processes for their preparation, pharmaceutical compositions containing them and their medical use. The compounds of formula I are as follows: having a formula (I) wherein R represents the ring A or 2-pyridinyl or 2-pyridinyl-N-oxide; R1 is selected from the group consisting of halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups; R2 and R3, which may be the same or different, each independently are selected from the group consisting of hydrogen atoms, halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groupss; n represents zero, 1 or 2; and pharmaceutically acceptable salts and solvates thereof.
Claims2
A method for treating depression in a mammal which comprises administering to said mammal an anti-depressive amount of an NK1 antagonist and a pharmaceutically acceptable carrier.
A method for treating depression in a mammal which comprises administering to said mammal an anti-depressive amount of an NK1 antagonist and a pharmaceutically acceptable carrier, wherein the NK1 antagonist is a compound having a formula (I)
- wherein
- R represents the ring A
- or 2-pyridinyl or 2-pyridinyl-N-oxide;
- R1 is selected from the group consisting of halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl, and S(O)nC1-4alkyl groups;
- R2 and R3, which may be the same or different, each independently are selected from the group consisting of hydrogen atoms, halogen atoms, C1-4alkyl, C1-4alkoxy, trifluoromethyl and cyano groupss;
- n represents zero, 1 or 2;
- and pharmaceutically acceptable salts and solvates thereof.
Dependencies are inferred from the claim text.